Skip to content

Replimune Group REPL Operating Income

Operating Income at other companies

Amgen logo
AmgenAMGN
$2.67B+126%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$642.9M+8.7%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$30.93M+27.9%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
CG Oncology logo
CG OncologyCGON
-$66.39M-57.3%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$187.91M-427%

Other financials

Income statement

See full
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's operating income?
Replimune Group (REPL) reported operating income of -$71.87M in Q4 2025.
How has Replimune Group's operating income changed year-over-year?
Replimune Group's operating income decreased by 8.9% year-over-year, from -$66.02M to -$71.87M.
What is the long-term trend for Replimune Group's operating income?
Over 3 years (2022 to 2025), Replimune Group's operating income has grown at a 30.3% compound annual growth rate (CAGR), from -$118.31M to -$261.63M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.